telemedicine in pediatric medicine based upon our institutional experience. Further research is needed to better understand the lack of utilization of telemedicine in pediatric urology as a means to improve on the delivery of healthcare. The objective of this study was to quantify the direct healthcare costs and indirect costs due to work loss associated with OAB in the United States (US).
INTRODUCTION AND OBJECTIVES:
The impact of overactive bladder (OAB) on costs due to time lost from work is not well known. The objective of this study was to quantify the direct healthcare costs and indirect costs due to work loss associated with OAB in the United States (US).
METHODS: Adults 18 years of age with an OAB diagnosis or OAB prescription therapy between 1/1/2008 and 12/31/2013 were identified from the MarketScanâ administrative claims databases (index date ¼ qualifying claim date). Patients were required to have 12 months of pre-and 1 month of post-index continuous enrollment. Data on work loss due to absence and short-term disability (STD) were available for subsets of the overall study population. Each OAB cohort was propensity score-matched to an equivalent number of non-OAB controls. Estimates of total per-patient per-month (PPPM) direct healthcare costs, as well as estimates of indirect costs attributable to absence and STD were modeled using ordinary least squares regression. The level of statistical significance for all tests was set at 0.05.
RESULTS: 110,059 OAB patients were identified, 9.8% of whom had work absence data and 49.3% had STD data. Average adjusted PPPM healthcare costs were significantly higher among OAB patients than non-OAB matched controls ($3,003.42 vs. $1,122.80, p<0.0001) . Similarly, among patients with STD eligibility, those with OAB incurred significantly higher PPPM indirect costs attributable to STD compared to non-OAB controls ($114.23 vs. $98.31, p¼0.0192) when adjusted within the framework of a two-part model. PPPM indirect costs of work loss due to absence did not differ significantly between patients with OAB and non-OAB matched control patients ($1,412.27 vs. $1,350.56, p¼0.4398) .
CONCLUSIONS: Patients with OAB incurred 2.5 times the healthcare costs of patients without OAB. OAB patients incurred more work loss and costs due to STD than non-OAB controls. Indirect costs attributable to workplace absence, however, did not differ for OAB patients and non-OAB controls. METHODS: We built a cohort of aged Medicare beneficiaries from 2010 through 2013 comprising 17,779,120 person-years and 9,201,163 person-years before and after ACO enrollment, respectively. We characterized our exposure of interest, ACO enrollment, by identifying all MSSP-enrolled primary care providers and recapitulating published attribution strategies, and identified our outcome, PSA screening, through relevant Medicare claims. Using claims from 2006, we fit a model for 5-year overall survival and isolated the highest and lowest quintiles of predicted survival. We then performed differences-indifferences analysis specifically evaluating the interaction between ACO enrollment and the period following ACO intervention (ACO X Post) within the highest and lowest quintiles of predicted survival to characterize between-group differences in change in prostate cancer screening attributable to ACO enrollment across the spectrum of health.
RESULTS: Medicare beneficiaries in the highest and lowest quintiles of predicted survival attributed to MSSP ACO-enrolled PCPs were 4.3% and 1.8% more likely to undergo PSA screening than those attributed to non-ACO primary care providers prior to deployment of the MSSP (p<0.0001 for both). MSSP enrollment was associated with excess reduction in the rate of prostate cancer screening among both appropriate candidates (highest quintile of survival) and inappropriate candidates (lowest quintile of predicted survival), with observed difference-in-difference of 0.86% and 0.67%, respectively ( Figure) .
CONCLUSIONS: ACO enrollment increases the magnitude of observed reductions in prostate cancer screening among both appropriate and inappropriate candidates for early detection. Developing and deploying incentives to target screening to appropriate candidates and withholding screening from those unlikely to benefit will be necessary to optimize early cancer detection in the era of payment innovation. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e409
